ArticleInfluenza and other respiratory viruses2015
Detection of influenza A and B with the Alere ™ i Influenza A & B: a novel isothermal nucleic acid amplification assay.
Article in Influenza and other respiratory viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections.Clinical microbiology reviews · 2019Guideline
- ERS/ESCMID state-of-the-science statement on the role of rapid diagnostic tests for the diagnosis and management of community-acquired lower respiratory tract infections.The European respiratory journal · 2026Review
- Rapid diagnosis of acute pediatric respiratory infections with Point-of-Care and multiplex molecular testing.Infection · 2025Review
- Early monitoring-to-warning Internet of Things system for emerging infectious diseases via networking of light-triggered point-of-care testing devices.Exploration (Beijing, China) · 2023Article
- Electro-Nano Diagnostic Platform Based on Antibody-Antigen Interaction: An Electrochemical Immunosensor for Influenza A Virus Detection.Biosensors · 2023Article
- Disposable platform for bacterial lysis and nucleic acid amplification based on a single USB-powered printed circuit board.PloS one · 2023Article
- Near-digital amplification in paper improves sensitivity and speed in biplexed reactions.Scientific reports · 2022Article
- Article
- Advances in the Rapid Diagnostic of Viral Respiratory Tract Infections.Frontiers in cellular and infection microbiology · 2022Review
- Diagnostic Accuracy of the Quidel Sofia Rapid Influenza Fluorescent Immunoassay in Patients with Influenza-like Illness: A Systematic Review and Meta-analysis.Tuberculosis and respiratory diseases · 2021Article
- Methods of Respiratory Virus Detection: Advances towards Point-of-Care for Early Intervention.Micromachines · 2021Review
- Two-Fluorophore Mobile Phone Imaging of Biplexed Real-Time NAATs Overcomes Optical Artifacts in Highly Scattering Porous Media.Analytical chemistry · 2020Article
- Improved performances of the second generation of the ID NOW influenza A&B 2® and comparison with the GeneXpert®.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.BMC infectious diseases · 2020Article
- Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020Article
- The impact of point-of-care testing for influenza A and B on patient flow and management in a medical assessment unit of a general hospital.BMC research notes · 2020Article
- Comparison of the ID Now Influenza A & B 2, Cobas Influenza A/B, and Xpert Xpress Flu Point-of-Care Nucleic Acid Amplification Tests for Influenza A/B Virus Detection in Children.Journal of clinical microbiology · 2020Article
- Advances in Directly Amplifying Nucleic Acids from Complex Samples.Biosensors · 2019Review
- Cost-Effective Respiratory Virus Testing.Journal of clinical microbiology · 2019Review
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapid influenza diagnostic tests (RIDTs) have an important role in clinical decision-making; however, the performances of currently available assays vary widely.
objectivesWe evaluated the performance of the Alere(™) i Influenza A&B (Alere(™) iNAT), a rapid isothermal nucleic acid amplification assay that has recently received FDA clearance, for the detection of influenza A and B viruses during the Australian influenza season of 2013. Results were compared to two other RIDTs tested in parallel; Quidel Sofia(®) Influenza A+B fluorescent immunoassay (FIA) and Alere(™) BinaxNOW(®) Influenza A & B immunochromatographic (ICT) assay.
methodsA total of 202 paired nasopharyngeal swabs collected from patients ≥ 16 years old with an influenza-like illness (ILI) were eluted in 2 ml of universal transport medium (UTM) that was used to perform all three RIDTs in parallel. Reverse-transcription polymerase chain reaction (RT-PCR) was used as the reference standard.
resultsCompared to RT-PCR, Alere(™) iNAT detected 77.8% influenza A positive samples versus 71.4% and 44.4% for the Quidel Sofia(®) Influenza A+B FIA and BinaxNOW(®) Influenza A & B ICT assay, respectively. For influenza B, Alere(™) iNAT detected 75% of those positive by RT-PCR, versus 33.3% and 25.0% for Sofia(®) and BinaxNOW(®), respectively. The specificity of Alere(™) iNAT was 100% for influenza A and 99% for influenza B.
conclusionsAlere(™) i Influenza A&B is a promising new rapid influenza diagnostic assay with potential point-of-care applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.